ATAC - Antibody therapy against coronavirus (COVID-2019)
Passive immunotherapy, through the transfer of antibodies, has been proposed as a potential approach for treating patients with COVID-19. Building on previous experience of antibody therapy against SARS- and MERS-CoV, scientists of the EU-funded ATAC project will characterise human antibodies obtained from the blood of recovered coronavirus patients from China and Italy. Using a combination of experimental and computational work, they will optimise, produce and test all antibodies before selecting the most effective candidate for therapy. The rapid dissemination of the project's results will help the medical community respond to the current COVID-19 pandemic through improved patient management.